Sepsis-reloaded: Next Generation Diagnostics, Biomarkers and Treatment Strategies

Sepsis is a life-threatening syndrome driven by a dysregulated host response to infection, resulting in high global morbidity, mortality, and economic burden. Despite advances in critical care, sepsis remains a major challenge, especially in low-and-middle-income countries where the incidence and mortality are highest. The condition arises from diverse infections, and it is characterized by rapid disease progression, variable clinical presentations, and emerging antimicrobial resistance. Prompt diagnosis is crucial; however, conventional tools such as clinical criteria and standard biomarkers often lack adequate sensitivity and specificity. Sepsis is very dangerous, so clinicians must diagnose it early. Traditional methods may often give false results; therefore, newer biomarkers have been explored. Procalcitonin can detect sepsis in about 75-80% of true cases, with a similar rate of correctly ruling out non-sepsis, achieving an AUC of around 0.78 (95% CI 0.74-0.82). Presepsin shows an AUC of 0.89-0.95 and performs even better, accurately identifying sepsis with a sensitivity of about 85-90% in medium-to-large clinical studies. Interleukin-6 is a key pro-inflammatory cytokine that rises rapidly within 1-2 hours during sepsis, driving cytokine storms and predicting severity and mortality, with strong diagnostic performance (sensitivity around 80-85%, AUC 0.86-0.94). However, due to its elevation in non-infectious inflammatory conditions, it is most effective when used in combination with other markers, such as procalcitonin or clinical scoring systems (e.g., QSOFA), to achieve diagnostic accuracy above 90%. MicroRNAs are small non-coding RNAs that are dysregulated in sepsis; they enable early diagnosis and prognosis via blood or plasma detection and can predict organ failure and mortality, but still require robust clinical validation. These biomarkers collectively offer improved diagnostic accuracy and risk stratification. Contemporary management emphasizes early recognition, rapid administration of intravenous antibiotics and fluids, and individualized targeted, supportive therapies (e.g., immunomodulators, monoclonal antibodies), pathogen- associated molecule removal, and novel drug delivery systems (e.g., nanoparticles), which aim to enhance precision and minimize toxicity. Imaging and microbiological investigations remain essential for identifying infection sources and guiding therapy. Key challenges include diagnostic delays, altered pharmacokinetics due to organ dysfunction, inadequate drug targeting, and limited resources in vulnerable populations. Future directions involve integrating multi-omics diagnostics, personalized therapeutics, and equitable resource allocation to reduce the overall global impact of sepsis. Continued research and international collaboration are vital for advancing diagnosis, innovative treatments, and comprehensive prevention strategies.